REVIEW PAPER
Cigarette smoking: an important renal risk factor – far beyond carcinogenesis
SR Orth 1  
 
 
More details
Hide details
1
Division of Nephrology and Hypertension, University Hospital Berne (Inselspital), Berne, Switzerland
CORRESPONDING AUTHOR
SR Orth   

Division of Nephrology and Hypertension, University Hospital of Berne (Inselspital), Freiburgstrasse 10, CH-3010 Berne, Switzerland
Publish date: 2003-06-15
 
Tobacco Induced Diseases 2003;1(June):137
KEYWORDS
ABSTRACT
In recent years, it has become apparent that smoking has a negative impact on renal function, being one of the most important remediable renal risk factors. It has been clearly shown that the risk for high-normal urinary albumin excretion and microalbuminuria is increased in smoking compared to non-smoking subjects of the general population. Data from the Multiple Risk Factor Intervention Trial (MRFIT) indicate that at least in males, smoking increases the risk to reach end-stage renal failure. Smoking is particularly “nephrotoxic” in older subjects, subjects with essential hypertension and patients with preexisting renal disease. Of interest, the magnitude of the adverse renal effect of smoking seems to be independent of the underlying renal disease. Death-censored renal graft survival is decreased in smokers, indicating that smoking also damages the renal transplant. Cessation of smoking has been show to reduce the rate of progression of renal failure both in patients with renal disease or a renal transplant. The mechanisms of smoking-induced renal damage are only partly understood and comprise acute hemodynamic (e.g., increase in blood pressure and presumably intraglomerular pressure) and chronic effects (e.g., endothelial cell dysfunction). Renal failure per se leads to an increased cardiovascular risk. The latter is further aggravated by smoking. Particularly survival of smokers with diabetes mellitus on hemodialysis is abysmal. In the present review article the current state of knowledge about the renal risks of smoking is reviewed. It is the aim of the article to point out that smoking not only increases the risk of renal cell carcinoma or uroepithelial cell carcinoma, but also the risk of a faster decline of renal function. The latter is a relatively new negative aspect which has not been widely recognized.
 
REFERENCES (201)
1.
Lickint F: Tabak und Organismus. Handbuch der gesamten Tabakkunde. 1939, Stuttgart: Hippocrates-Verlag.
 
2.
Christiansen JS: Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care. 1978, 1: 146-149.
 
3.
Mühlhauser I: Cigarette smoking and diabetes: an update. Diabetic Medicine. 1994, 11: 336-343.
 
4.
Orth SR: Smoking and the kidney. Journal of the American Society of Nephrology. 2002, 13: 1663-1672.
 
5.
Orth SR, Ritz E, Schrier RW: The renal risks of smoking. Kidney International. 1997, 51: 1669-1677.
 
6.
Orth SR, Viedt C, Ritz E: Adverse effects of smoking in the renal patient. Tohoku Journal of Experimental Medicine. 2001, 194: 1-15.
 
7.
Orth SR: Smoking–a renal risk factor. Nephron. 2000, 86: 12-26.
 
8.
Hays JT, Dale LC, Hurt RD, Croghan IT: Trends in smoking-related diseases. Why smoking cessation is still the best medicine. Postgraduate Medicine. 1998, 104: 56-62. 65–56, 71.
 
9.
Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Annals of Internal Medicine. 2000, 133: 585-591.
 
10.
Janssen WM, Hillege H, Pinto-Sietsma SJ, Bak AA, De Zeeuw D, de Jong PE: Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clinical Chemistry and Laboratory Medicine. 2000, 38: 1107-1110.
 
11.
Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. Journal of Internal Medicine. 2001, 249: 519-526.
 
12.
Halimi JM, Giraudeau B, Vol S, Caces E, Nivet H, Lebranchu Y, Tichet J: Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney International. 2000, 58: 1285-1292.
 
13.
Hogan SL, Colindres RE, Cai J, Coresh J: Association of smoking with albuminuria in a cross-sectional probability sample of U.S. adults. Journal of the American Society of Nephrology. 2001, 12: 209A.
 
14.
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. The New England Journal of Medicine. 1996, 334: 13-18.
 
15.
Whelton PK, Randall B, Neaton J, Stamler J, Brancati FL, Klag MJ: Cigarette smoking and ESRD incidence in men screened for the MRFIT. Journal of the American Society of Nephrology. 1995, 6: 408a.
 
16.
Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG: Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney International. 2000, 57: 2072-2079.
 
17.
Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. Journal of the American Geriatric Society. 1985, 33: 278-285.
 
18.
Fliser D, Franek E, Ritz E: Renal function in the elderly–is the dogma of an inexorable decline of renal function correct?. Nephrology Dialysis Transplantation. 1997, 12: 1553-1555.
 
19.
Goetz FC, Jacobs DR, Chavers B, Roel J, Yelle M, Sprafka JM: Risk factors for kidney damage in the adult population of Wadena, Minnesota. A prospective study. American Journal of Epidemiology. 1997, 145: 91-102.
 
20.
Ritz E, Nowicki M, Fliser D, Hörner D, Klimm HP: Proteinuria and hypertension. Kidney International Supplement. 1994, 47: S76-80.
 
21.
Mimran A, Ribstein J, Du Cailar G: Microalbuminuria in essential hypertension. Current Opinion in Nephrology and Hypertension. 1999, 8: 359-363.
 
22.
Luft FC: Microalbuminuria and essential hypertension: renal and cardiovascular implications. Current Opinion in Nephrology and Hypertension. 1997, 6: 553-557.
 
23.
Agewall S, Wikstrand J, Ljungman S, Fagerberg B: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. American Journal of Cardiology. 1997, 80: 164-169.
 
24.
Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arteriosclerosis Thrombosis and Vascular Biology. 1999, 19: 617-624.
 
25.
Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000, 35: 898-903.
 
26.
Ruilope LM, van Veldhuisen DJ, Ritz E, Lüscher TF: Renal function: the Cinderella of cardiovascular risk profile. Journal of the American College of Cardiology. 2001, 38: 1782-1787.
 
27.
Mimran A, Ribstein J, DuCailar G, Halimi JM: Albuminuria in normals and essential hypertension. Journal of Diabetes Complications. 1994, 8: 150-156.
 
28.
Hörner D, Fliser D, Klimm HP, Ritz E: Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. Journal of Hypertension. 1996, 14: 655-660.
 
29.
Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000, 23 (Suppl 2): B35-39.
 
30.
Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Journal of Hypertension. 2002, 20: 405-412.
 
31.
Regalado M, Yang S, Wesson DE: Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. American Journal of Kidney Diseases. 2000, 35: 687-694.
 
32.
Perry HM, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995, 25: 587-594.
 
33.
Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T: Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Medica Scandinavica. 1984, 215: 63-68.
 
34.
Nórden G, Nyberg G: Smoking and diabetic nephropathy. Acta Medica Scandinavica. 1984, 215: 257-261.
 
35.
Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, Hamman RE: Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. Journal of the American Medical Association. 1991, 265: 614-617.
 
36.
Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Microalbuminuria Collaborative Study Group, United Kingdom. British Medical Journal. 1993, 306: 1235-1239.
 
37.
Corradi L, Zoppi A, Tettamanti F, Malamani G, Lazzari P, Fogari R: Association between smoking and microalbuminuria in hypertensive patients with type 2 diabetes mellitus. Journal of Hypertension Supplement. 1993, 11 (Suppl 5): S190-191.
 
38.
Olivarius Nde F, Andreasen AH, Keiding N, Mogensen CE: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia. 1993, 36: 1007-1016.
 
39.
Almdal T, Norgaard K, Feldt-Rasmussen B, Deckert T: The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care. 1994, 17: 120-125.
 
40.
Couper JJ, Staples AJ, Cocciolone R, Nairn J, Badcock N, Henning P: Relationship of smoking and albuminuria in children with insulin-dependent diabetes. Diabetic Medicine. 1994, 11: 666-669.
 
41.
Chaturvedi N, Stephenson JM, Fuller JH: The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care. 1995, 18: 785-792.
 
42.
Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW: Clinical factors associated with urinary albumin excretion in type II diabetes. American Journal of Kidney Diseases. 1995, 25: 836-844.
 
43.
Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, D'Errico N, Deambrogio P, Pagano G: Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care. 1996, 19: 43-47.
 
44.
Keller CK, Bergis KH, Fliser D, Ritz E: Renal findings in patients with short-term type 2 diabetes. Journal of the American Society of Nephrology. 1996, 7: 2627-2635.
 
45.
Renal involvement in type 1 (IDDM) diabetes in Spain. ESTUDIO DIAMANTE. Diabetes Research and Clinical Practice. 1997, 38: 129-137.
 
46.
Mühlhauser I, Sawicki P, Berger M: Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. Diabetologia. 1986, 29: 500-502.
 
47.
Stegmayr B, Lithner F: Tobacco and end stage diabetic nephropathy. British Medical Journal (Clinical Research ED). 1987, 295: 581-582.
 
48.
Nórden G: Diabetic nephropathy. A clinical study of risk factors in type-I diabetes mellitus. Scandinavian Journal of Urology and Nephrology. 1988, 1-76. Suppl 116.
 
49.
Stegmayr BG: A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. Journal of Internal Medicine. 1990, 228: 121-124.
 
50.
Klein R, Klein BE, Moss SE: Incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes. 1993, 42: 381-389.
 
51.
Klein R, Klein BE, Moss SE, Cruickshanks KJ: Ten-year incidence of gross proteinuria in people with diabetes. Diabetes. 1995, 44: 916-923.
 
52.
Biesenbach G, Janko O, Zazgornik J: Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrology Dialysis Transplantation. 1994, 9: 1097-1102.
 
53.
Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M: Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994, 17: 126-131.
 
54.
Biesenbach G, Grafinger P, Janko O, Zazgornik J: Influence of cigarette-smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clinical Nephrology. 1997, 48: 146-150.
 
55.
Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, Ujihara U, Takahashi C, Omori Y: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia. 1997, 40: 405-411.
 
56.
Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Salling N, Deckert T, Nerup J: The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications. Diabetic Medicine. 1987, 4: 201-210.
 
57.
Mackin P, Macleod JM, New JP, Marshall SM: Renal function in long-duration type I diabetes. Diabetes Care. 1996, 19: 249-251.
 
58.
Perna A, Iordache BE, Bettinaglio P, Ruggenenti P, Noris M, Galbusera A, Caprioli J, Rubis N, Gritti D, Fassi A, Remuzzi G: DD ACE genotype and smoking cluster with high-normal albuminuria: A cross sectional analysis in 1209 normoalbuminuric type 2 diabetics enrolled in the BErgamo NEphrologic DIabetes Complications Trial (BENEDICT). Journal of the American Society of Nephrology. 2001, 12: 154A.
 
59.
Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. British Medical Journal. 1996, 313: 779-784.
 
60.
Chuahirun T, Wesson DE: Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. American Journal of Kidney Diseases. 2002, 39: 376-382.
 
61.
Orth SR, Stöckmann A, Conradt C, Ritz E, in collaboration with Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schäfer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney International. 1998, 54: 926-931.
 
62.
Chalon S, Moreno H, Hoffman BB, Blaschke TF: Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers. Clinical Pharmacology and Therapeutics. 1999, 65: 295-303.
 
63.
Ota Y, Kugiyama K, Sugiyama S, Ohgushi M, Matsumura T, Doi H, Ogata N, Oka H, Yasue H: Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract–role of free radicals and attenuation by captopril. Atherosclerosis. 1997, 131: 195-202.
 
64.
Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, Passan DR, Williams GH, Hollenberg NK: The paradox of the low-renin state in diabetic nephropathy. Journal of the American Society of Nephrology. 1999, 10: 2382-2391.
 
65.
Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. The New England Journal of Medicine. 1999, 341: 1127-1133.
 
66.
Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC: Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. British Medical Journal. 1995, 310: 555-559.
 
67.
Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG: Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. British Medical Journal. 1995, 310: 560-564.
 
68.
Nakanishi N, Nakamura K, Matsuo Y, Suzuki K, Tatara K: Cigarette smoking and risk for impaired fasting glucose and type 2 diabetes in middle-aged Japanese men. Annals of Internal Medicine. 2000, 133: 183-191.
 
69.
Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T: Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care. 1992, 15: 1181-1191.
 
70.
Faronato PP, Maioli M, Tonolo G, Brocco E, Noventa F, Piarulli F, Abaterusso C, Modena F, de Bigontina G, Velussi M, Inchiostro S, Santeusanio F, Bueti A, Nosadini R: Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Diabetologia. 1997, 40: 816-823.
 
71.
Wirta O, Pasternack A, Mustonen J, Laippala P, Lahde Y: Retinopathy is independently related to microalbuminuria in type 2 diabetes mellitus. Clinical Nephrology. 1999, 51: 329-334.
 
72.
Colhoun HM, Lee ET, Bennett PH, Lu M, Keen H, Wang SL, Stevens LK, Fuller JH: Risk factors for renal failure: the WHO Mulinational Study of Vascular Disease in Diabetes. Diabetologia. 2001, 44 (Suppl 2): S46-53.
 
73.
Segato T, Midena E, Grigoletto F, Zucchetto M, Fedele D, Piermarocchi S, Crepaldi G: The epidemiology and prevalence of diabetic retinopathy in the Veneto region of north east Italy. Veneto Group for Diabetic Retinopathy. Diabetic Medicine. 1991, 8 (Spec No): S11-16.
 
74.
Moss SE, Klein R, Klein BE: Association of cigarette smoking with diabetic retinopathy. Diabetes Care. 1991, 14: 119-126.
 
75.
Chen MS, Kao CS, Chang CJ, Wu TJ, Fu CC, Chen CJ, Tai TY: Prevalence and risk factors of diabetic retinopathy among noninsulin-dependent diabetic subjects. American Journal of Ophthalmology. 1992, 114: 723-730.
 
76.
Moss SE, Klein R, Klein BE: Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology. 1996, 103: 1438-1442.
 
77.
Janghorbani M, Jones RB, Allison SP: Incidence of and risk factors for proliferative retinopathy and its association with blindness among diabetes clinic attenders. Ophthalmic Epidemiology. 2000, 7: 225-241.
 
78.
Keen H, Lee ET, Russell D, Miki E, Bennett PH, Lu M: The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001, 44 (Suppl 2): S22-30.
 
79.
Paetkau ME, Boyd TA, Winship B, Grace M: Cigarette smoking and diabetic retinopathy. Diabetes. 1977, 26: 46-49.
 
80.
Sparrow JM, McLeod BK, Smith TD, Birch MK, Rosenthal AR: The prevalence of diabetic retinopathy and maculopathy and their risk factors in the non-insulin-treated diabetic patients of an English town. Eye. 1993, 7: 158-163.
 
81.
Yaqoob M, Bell GM, Percy DF, Finn R: Primary glomerulonephritis and hydrocarbon exposure: a case-control study and literature review. Quarterly Journal of Medicine. 1992, 83: 409-418.
 
82.
Merkel F, Pullig O, Marx M, Netzer KO, Weber M: Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases. Nephrology Dialysis Transplantation. 1994, 9: 372-376.
 
83.
Wakai K, Kawamura T, Matsuo S, Hotta N, Ohno Y: Risk factors for IgA nephropathy: a case-control study in Japan. American Journal of Kidney Diseases. 1999, 33: 738-745.
 
84.
Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ: Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. Journal of the American Society of Nephrology. 2001, 12: 134-142.
 
85.
Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology. 1994, 5: 1349-1354.
 
86.
Stengel B, Couchoud C, Cenee S, Hemon D: Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney International. 2000, 57: 2519-2526.
 
87.
Samuelsson O, Attman PO: Is smoking a risk factor for progression of chronic renal failure?. Kidney International. 2000, 58: 2597.
 
88.
Nielsen MM, Hjollund E: Smoking and diabetic microangiopathy. The Lancet. 1978, 2: 533-534.
 
89.
Lhotta K, Rumpelt JH, König P, Mayer G, Kronenberg F: Cigarette smoking and vascular pathology in renal biopsies. Kidney International. 2002, 61: 648-654.
 
90.
Ward MM, Studenski S: Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Archives of Internal Medicine. 1992, 152: 2082-2088.
 
91.
Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A, Darnell A, Ingelmo M: Cardiovascular risk factors and the long-term outcome of lupus nephritis. Quarterly Journal of Medicine. 2001, 94: 19-26.
 
92.
Sessa A, Meroni M, Battini G, Vaccari M, Giordano F, Torri Tarelli L: Cigarette smoking and pauci-immune extracapillary glomerulonephritis with ANCA-associated idiopathic systemic vasculitis. A retrospective study. Contributions to Nephrology. 2000, 130: 103-108.
 
93.
Michael Pittilo R: Cigarette smoking, endothelial injury and cardiovascular disease. International Journal of Experimental Pathology. 2000, 81: 219-230.
 
94.
Wisnieski JJ, Baer AN, Christensen J, Cupps TR, Flagg DN, Jones JV, Katzenstein PL, McFadden ER, McMillen JJ, Pick MA, et al: Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Baltimore). 1995, 74: 24-41.
 
95.
Donaghy M, Rees AJ: Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. The Lancet. 1983, 2: 1390-1393.
 
96.
Herody M, Duvic C, Noel LH, Nedelec G, Grunfeld JP: Cigarette smoking and other inhaled toxins in anti-GBM disease. Contributions to Nephrology. 2000, 130: 94-102.
 
97.
Textor SC, Wilcox CS: Renal artery stenosis: a common, treatable cause of renal failure?. Annual Review of Medicine. 2001, 52: 421-442.
 
98.
Metcalfe W, Reid AW, Geddes CC: Prevalence of angiographic atherosclerotic renal artery disease and its relationship to the anatomical extent of peripheral vascular atherosclerosis. Nephrology Dialysis Transplantation. 1999, 14: 105-108.
 
99.
Appel RG, Bleyer AJ, Reavis S, Hansen KJ: Renovascular disease in older patients beginning renal replacement therapy. Kidney International. 1995, 48: 171-176.
 
100.
Abdella N, Mojiminiyi OA, Akanji AO: Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease. Diabetes Research and Clinical Practice. 2000, 50: 177-185.
 
101.
Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J: Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. American Journal of Clinical Nutrition. 2001, 73: 613-621.
 
102.
Hadj-Abdelkader M, Alphonse JC, Boyer L, Younes H, Deteix P: Smoking and atheromatous stenosis of the renal arteries. Archives des Maladies du Coeur et des Vaisseaux. 2001, 94: 925-927.
 
103.
Alcazar JM, Marin R, Gomez-Campdera F, Orte L, Rodriguez-Jornet A, Mora-Macia J: Clinical characteristics of ischaemic renal disease. Nephrology Dialysis Transplantation. 2001, 16 (Suppl 1): 74-77.
 
104.
Jaboureck O, Mounier-Vehier C, Devos P, Lions C, Dequiedt P, Beregi JP, Carre A: Are demographic characteristics of hypertensive patients different with renal artery stenosis?. Archives des Maladies du Coeur et des Vaisseaux. 2001, 94: 828-833.
 
105.
Shurrab AE, Mamtora H, O'Donoghue D, Waldek S, Kalra PA: Increasing the diagnostic yield of renal angiography for the diagnosis of atheromatous renovascular disease. British Journal of Radiology. 2001, 74: 213-218.
 
106.
Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, Maiorca R: Cholesterol crystal embolism: A recognizable cause of renal disease. American Journal of Kidney Diseases. 2000, 36: 1089-1109.
 
107.
Ribera Pibernat M, Bigata Viscasillas X, Fuentes Gonzalez MJ, Bielsa Marsol I, Ferrandiz Foraster C: Cholesterol embolism disease: study of 16 cases. Revista Clinica Espanola. 2000, 200: 659-663.
 
108.
Main J: How important is atheromatous renal artery stenosis as a cause of end-stage renal disease?. Seminars in Dialysis. 2001, 14: 143-145.
 
109.
Baggio B, Budakovic A, Casara D, Gambaro G, Saladini G, Piccoli A, Verlato F: Renal involvement in subjects with peripheral atherosclerosis. Journal of Nephrology. 2001, 14: 286-292.
 
110.
Leavey SF, Strawderman RL, Young EW, Saran R, Roys E, Agodoa LY, Wolfe RA, Port FK: Cross-sectional and longitudinal predictors of serum albumin in hemodialysis patients. Kidney International. 2000, 58: 2119-2128.
 
111.
Khan IH, Catto GR, Edward N, MacLeod AM: Death during the first 90 days of dialysis: a case control study. American Journal of Kidney Diseases. 1995, 25: 276-280.
 
112.
Owen WF, Madore F, Brenner BM: An observational study of cardiovascular characteristics of long-term end-stage renal disease survivors. American Journal of Kidney Diseases. 1996, 28: 931-936.
 
113.
Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney International. 2000, 58: 353-362.
 
114.
Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. Journal of the American Society of Nephrology. 2001, 12: 1516-1523.
 
115.
Franga DL, Kratz JM, Crumbley AJ, Zellner JL, Stroud MR, Crawford FA: Early and long-term results of coronary artery bypass grafting in dialysis patients. Annals of Thoracic Surgery. 2000, 70: 813-819.
 
116.
Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Cardiac disease in diabetic end-stage renal disease. Diabetologia. 1997, 40: 1307-1312.
 
117.
Akmal M: Hemodialysis is diabetic patients. American Journal of Kidney Diseases. 2001, 38: S195-199.
 
118.
Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D'Agati VD: Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Human Pathology. 2002, 33: 826-835.
 
119.
Koch M, Thomas B, Tschöpe W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia. 1993, 36: 1113-1117.
 
120.
Biesenbach G, Zazgornik J: Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care. 1996, 19: 625-628.
 
121.
Malatino LS, Benedetto FA, Mallamaci F, Tripepi G, Zoccali C, Parlongo S, Cutrupi S, Marino C, Panuccio V, Garozzo M, et al: Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. Journal of Nephrology. 1999, 12: 256-260.
 
122.
O'Hare AM, Hsu Cy CY, Bacchetti P, Johansen KL: Peripheral Vascular Disease Risk Factors among Patients Undergoing Hemodialysis. Journal of the American Society of Nephrology. 2002, 13: 497-503.
 
123.
Fabbian F, Catalano C, Lambertini D, Tarroni G, Bordin V, Squerzanti R, Gilli P, Di Landro D, Cavagna R: Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clinical Nephrology. 2000, 54: 234-239.
 
124.
Blumberg A, Hausermann M, Strub B, Jenzer HR: Cardiac arrhythmias in patients on maintenance hemodialysis. Nephron. 1983, 33: 91-95.
 
125.
de Lima JJ, Vieira ML, Lopes HF, Gruppi CJ, Medeiros CJ, Ianhez LE, Krieger EM: Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients. American Journal of Hypertension. 1999, 12: 204-208.
 
126.
Steinberg AA, Mars RL, Goldman DS, Percy RF: Effect of end-stage renal disease on decreased heart rate variability. American Journal of Cardiology. 1998, 82: 1156-1158. A1110.
 
127.
Parfrey PS, Harnett JD: Clinical aspects of cardiomyopathy in dialysis patients. Blood Purification. 1994, 12: 267-276.
 
128.
Parfrey PS, Harnett JD, Griffiths S, Gault MH, Barre PE, Guttmann RD: Low-output left ventricular failure in end-stage renal disease. American Journal of Nephrology. 1987, 7: 184-191.
 
129.
Rocco MV, Soucie JM, Reboussin DM, McClellan WM: Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). Journal of the American Society of Nephrology. 1996, 7: 889-896.
 
130.
Wetzig GA, Gough IR, Furnival CM: One hundred cases of arteriovenous fistula for haemodialysis access: the effect of cigarette smoking on patency. Australian and New Zealand Journal of Surgery. 1985, 55: 551-554.
 
131.
Gokal R, Baillod R, Bogle S, Hunt L, Jakubowski C, Marsh F, Ogg C, Oliver D, Ward M, Wilkinson R: Multi-centre study on outcome of treatment in patients on continuous ambulatory peritoneal dialysis and haemodialysis. Nephrology Dialysis Transplantation. 1987, 2: 172-178.
 
132.
Zimmerman SW, Oxton LL, Bidwell D, Wakeen M: Long-term outcome of diabetic patients receiving peritoneal dialysis. Peritoneal Dialysis International. 1996, 16: 63-68.
 
133.
Wakeen M, Zimmerman SW: Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. American Journal of Kidney Diseases. 1998, 32: 488-493.
 
134.
Webb AT, Brown EA: Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International. 1993, 13 (Suppl 2): S406-408.
 
135.
Kutner NG, Zhang R, McClellan WM, Cole SA: Psychosocial predictors of non-compliance in haemodialysis and peritoneal dialysis patients. Nephrology Dialysis Transplantation. 2002, 17: 93-99.
 
136.
Halimi JM, al-Najjar A, Buchler M, Giraudeau B, Etienne I, Picou S, Marliere J, Nivet H, Lebranchu Y: Microalbuminuria in hypertensive, non-proteinuric renal transplant recipients: role of previous acute rejection episodes and sodium intake. Archives des Maladies du Coeur et des Vaisseaux. 2001, 94: 933-936.
 
137.
Hegeman RL, Hunsicker LG: Chronic rejection in renal allografts: importance of cardiovascular risk factors. Clinical Transplantation. 1995, 9: 135-139.
 
138.
Cho YW, Terasaki PI, Cecka JM: New variables reported to the UNOS registry and their impact on cadaveric renal transplant outcomes – a preliminary study. Clinical Transplantation. 1995, 405-415.
 
139.
Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM: Excess risk of renal allograft loss associated with cigarette smoking. Transplantation. 2001, 71: 1752-1757.
 
140.
Doyle SE, Matas AJ, Gillingham K, Rosenberg ME: Predicting clinical outcome in the elderly renal transplant recipient. Kidney International. 2000, 57: 2144-2150.
 
141.
Sijpkens YW, Doxiadis II, De Fijter JW, Mallat MJ, Van Es LA, De Lange P, Zwinderman AH, Westendorp RG, Van Kemenade FJ, Buijn JA, Claas FH, Paul LC: Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney International. 1999, 56: 1920-1927.
 
142.
Stone JH, Amend WJ, Criswell LA: Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. Arthritis and Rheumatism. 1998, 41: 1438-1445.
 
143.
Feduska NJ: Donor factors in cadaveric renal transplantation. Clinical Transplantation. 1993, 351-357.
 
144.
Cosio FG, Falkenhain ME, Pesavento TE, Yim S, Alamir A, Henry ML, Ferguson RM: Patient survival after renal transplantation: II. The impact of smoking. Clinical Transplantation. 1999, 13: 336-341.
 
145.
Kasiske BL, Klinger D: Cigarette smoking in renal transplant recipients. Journal of the American Society of Nephrology. 2000, 11: 753-759.
 
146.
Ritz E, Schwenger V, Wiesel M, Zeier M: Atherosclerotic complications after renal transplantation. Transplantation International. 2000, 13 (Suppl 1): S14-19.
 
147.
Kasiske BL: Ischemic heart disease after renal transplantation. Kidney International. 2002, 61: 356-369.
 
148.
Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology. 1996, 7: 158-165.
 
149.
Nankivell BJ, Lau SG, Chapman JR, O'Connell PJ, Fletcher JP, Allen RD: Progression of macrovascular disease after transplantation. Transplantation. 2000, 69: 574-581.
 
150.
Sung RS, Althoen M, Howell TA, Merion RM: Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. Transplantation. 2000, 70: 1049-1054.
 
151.
Kalker AJ, Pirsch JD, Heisey D, Sollinger HW, Belzer FO, Knechtle SJ, D'Alessandro AM: Foot problems in the diabetic transplant recipient. Clinical Transplantation. 1996, 10: 503-510.
 
152.
Danpanich E, Kasiske BL: Risk factors for cancer in renal transplant recipients. Transplantation. 1999, 68: 1859-1864.
 
153.
Ramsay HM, Harden PN, Reece S, Smith AG, Jones PW, Strange RC, Fryer AA: Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. Journal of Investigative Dermatology. 2001, 117: 251-255.
 
154.
King GN, Healy CM, Glover MT, Kwan JT, Williams DM, Leigh IM, Worthington HV, Thornhill MH: Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. The New England Journal of Medicine. 1995, 332: 1052-1057.
 
155.
Joy MS, Neyhart CD, Dooley MA: A multidisciplinary renal clinic for corticosteroid-induced bone disease. Pharmacotherapy. 2000, 20: 206-216.
 
156.
Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM: Postrenal transplant erythrocytosis: a review of 53 patients. Kidney International. 1983, 23: 731-737.
 
157.
Hesse E: Der Einfluss des Rauchens auf den Kreislauf. Deutsches Archiv für Klinische Medizin. 1907, 89: 565-575.
 
158.
Aronow WS, Dendinger J, Rokaw SN: Heart rate and carbon monoxide level after smoking high-, low-, and non-nicotine cigarettes. A study in male patients with angina pectoris. Annals of Internal Medicine. 1971, 74: 697-702.
 
159.
Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del Bo A, Mancia G: Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994, 90: 248-253.
 
160.
Haass M, Kübler W: Nicotine and sympathetic neurotransmission. Cardiovascular Drugs and Therapy. 1997, 10: 657-665.
 
161.
Orth SR, Amann K, Strojek K, Ritz E: Sympathetic overactivity and arterial hypertension in renal failure. Nephrology Dialysis Transplantation. 2001, 16 (Suppl 1): 67-69.
 
162.
Minami J, Ishimitsu T, Matsuoka H: Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension. 1999, 33: 586-590.
 
163.
Mann SJ, James GD, Wang RS, Pickering TG: Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. Journal of the American Medical Association. 1991, 265: 2226-2228.
 
164.
Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G: Persistent blood pressure increase induced by heavy smoking. Journal of Hypertension. 1992, 10: 495-499.
 
165.
Hansen HP, Rossing K, Jacobsen P, Jensen BR, Parving HH: The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria. Scandinavian Journal of Clinical and Laboratory Investigation. 1996, 56: 393-399.
 
166.
Sawicki PT, Mühlhauser I, Bender R, Pethke W, Heinemann L, Berger M: Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. Journal of Internal Medicine. 1996, 239: 345-352.
 
167.
Poulsen PL, Ebbehoj E, Hansen KW, Mogensen CE: Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients. American Journal of Hypertension. 1998, 11: 1093-1099.
 
168.
Ritz E, Benck U, Franek E, Keller C, Seyfarth M, Clorius J: Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease. Journal of the American Society of Nephrology. 1998, 9: 1798-1804.
 
169.
Hansen KW, Pedersen MM, Christiansen JS, Mogensen CE: Night blood pressure and cigarette smoking: disparate association in healthy subjects and diabetic patients. Blood Pressure. 1994, 3: 381-388.
 
170.
Barna I, Kempler P, Büki B, de Chatel R: The influence of chronic smoking on the diurnal rhythm of blood pressure in healthy individuals and in insulin dependent diabetic patients. Nephrology Dialysis Transplantation. 1996, 11: A80.
 
171.
Halimi JM, Philippon C, Mimran A: Contrasting renal effects of nicotine in smokers and non-smokers. Nephrology Dialysis Transplantation. 1998, 13: 940-944.
 
172.
Gambaro G, Verlato F, Budakovic A, Casara D, Saladini G, Del Prete D, Bertaglia G, Masiero M, Checchetto S, Baggio B: Renal impairment in chronic cigarette smokers. Journal of the American Society of Nephrology. 1998, 9: 562-567.
 
173.
Benck U, Clorius JH, Zuna I, Ritz E: Renal hemodynamic changes during smoking: effects of adrenoreceptor blockade. European Journal of Clinical Investigation. 1999, 29: 1010-1018.
 
174.
Noronha-Dutra AA, Epperlein MM, Woolf N: Effect of cigarette smoking on cultured human endothelial cells. Cardiovascular Research. 1993, 27: 774-778.
 
175.
Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z: Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clinical Nephrology. 1999, 51: 233-241.
 
176.
Matsumoto N, Ishimura E, Taniwaki H, Emoto M, Shoji T, Kawagishi T, Inaba M, Nishizawa Y: Smoking and proteinuria impair vasodilatory response of intrarenal arteries to nitroglycerine in patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation. 2002, 17: 608-613.
 
177.
Leyen von der HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ: Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proceedings of the National Academy of Science USA. 1995, 92: 1137-1141.
 
178.
Shears LL, Kawaharada N, Tzeng E, Billiar TR, Watkins SC, Kovesdi I, Lizonova A, Pham SM: Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. Journal of Clinical Investigation. 1997, 100: 2035-2042.
 
179.
Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE: A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nature Medicine. 1996, 2: 41-45.
 
180.
Auerbach O, Hammond EC, Garfinkel L: Thickening of walls of arterioles and small arteries in relation to age and smoking habits. The New England Journal of Medicine. 1968, 278: 980-984.
 
181.
Auerbach O, Carter HW, Garfinkel L, Hammond EC: Cigarette smoking and coronary artery disease. A macroscopic and microscopic study. Chest. 1976, 70: 697-705.
 
182.
Black HR, Zeevi GR, Silten RM, Walker Smith GJ: Effect of heavy cigarette smoking on renal and myocardial arterioles. Nephron. 1983, 34: 173-179.
 
183.
Oberai B, Adams CW, High OB: Myocardial and renal arteriolar thickening in cigarette smokers. Atherosclerosis. 1984, 52: 185-190.
 
184.
Tracy RE, Malcom GT, Oalmann MC, Newman WP, Guzman MA: Nephrosclerosis, glycohemoglobin, cholesterol, and smoking in subjects dying of coronary heart disease. Modern Pathology. 1994, 7: 301-309.
 
185.
Bos WJ, Demircan MM, Weening JJ, Krediet RT, Wal van der AC: Renal vascular changes in renal disease independent of hypertension. Nephrology Dialysis Transplantation. 2001, 16: 537-541.
 
186.
Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR: Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney International. 2002, 61: 2090-2098.
 
187.
Budakovic A, Fioretto P, Saller A, Dalla Vestra M, Zotta L, Baggio B: Cigarette smoking and glomerular ultrastructure in type 2 diabetes. Journal of the American Society of Nephrology. 2001, 12: 143A.
 
188.
McMillan MA, Briggs JD, Junor BJ: Outcome of renal replacement treatment in patients with diabetes mellitus. British Medical Journal. 1990, 301: 540-544.
 
189.
Emmons KM: Smoking cessation and tobacco control: an overview. Chest. 1999, 116: 490S-492S.
 
190.
Yudkin JS: How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. British Medical Journal. 1993, 306: 1313-1318.
 
191.
Culleton BF, Wilson PW: Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. Journal of the American Society of Nephrology. 1998, 9: S5-15.
 
192.
Sleight P: Smoking and hypertension. Clinical and Experimental Hypertension. 1993, 15: 1181-1192.
 
193.
Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH: The primary prevention of myocardial infarction. The New England Journal of Medicine. 1992, 326: 1406-1416.
 
194.
Bauer UE, Johnson TM, Hopkins RS, Brooks RG: Changes in youth cigarette use and intentions following implementation of a tobacco control program: findings from the Florida Youth Tobacco Survey, 1998–2000. Journal of the American Medical Association. 2000, 284: 723-728.
 
195.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. The New England Journal of Medicine. 1999, 340: 685-691.
 
196.
Jorenby DE: Smoking cessation strategies for the 21st century. Circulation. 2001, 104: E51-52.
 
197.
Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R: Pharmacokinetics of nicotine in kidney failure. Clinical Pharmacology and Therapeutics. 2000, 68: 250-260.
 
198.
Cole TK: Smoking cessation in the hospitalized patient using the transtheoretical model of behavior change. Heart and Lung. 2001, 30: 148-158.
 
199.
Orth SR, Ritz E: Adverse effect of smoking on renal function in the general population: Are men at higher risk?. American Journal of Kidney Diseases. 2002, 40: 864-866.
 
200.
Briganti EM, Branley P, Chadban SJ, Shaw JE, McNeil JJ, Welborn TA, Atkins RC: Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Australian Diabets, Obesity and Lifestyle Study. American Journal of Kidney Diseases. 2002, 40: 704-712.
 
201.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Influence of smoking and obesity on the development of proteinuria. Kidney International. 2002, 62: 956-962.
 
 
CITATIONS (16):
1.
Different association of cigarette smoking with GFR estimated from serum creatinine and that from serum cystatin C in the general population
Yuichi Yamada, Yuka Noborisaka, Masao Ishizaki, Michiko Yamazaki, Ryumon Honda, Hitoshi Yokoyama, Tatsuyuki Kakuma
Clinical and Experimental Nephrology
 
2.
Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma
Matvey Tsivian, Daniel M. Moreira, Jorge R. Caso, Vladimir Mouraviev, Thomas J. Polascik
Journal of Clinical Oncology
 
3.
Impact of smoking on kidney transplantation outcomes
A. G. Stolyar, N. A. Tomilina
Terapevticheskii arkhiv
 
4.
Sub-acute administration of lower doses of nicotine caused sex-dependent improvement of renal function in Wistar rats
Ojo Rufus Akomolafe, Christian Eseigbe Imafidon, Olaoluwa Sesan Olukiran, Ayowole Abraham Oladele, Babatunde Oludare Akanji
Toxicology Reports
 
5.
Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis
Christopher A. Drummond, Pamela S. Brewster, Wencan He, Kaili Ren, Yanmei Xie, Katherine R. Tuttle, Steven T. Haller, Kenneth Jamerson, Lance D. Dworkin, Donald E. Cutlip, Timothy P. Murphy, Ralph B. D’Agostino, William L. Henrich, Jiang Tian, Joseph I. Shapiro, Christopher J. Cooper, Christophe Mariat
PLOS ONE
 
6.
Comparative Analysis of Smoking as a Risk Factor among Renal Cell Carcinoma Histological Subtypes
Neel H. Patel, Kristopher M. Attwood, Michael Hanzly, Terrance T. Creighton, Diana C. Mehedint, Thomas Schwaab, Eric C. Kauffman
The Journal of Urology
 
7.
Transient evoked otoacoustic emissions and vestibular evoked myogenic potentials in cigarette and water pipe smokers
Mohamed Wael Mohamed Mustafa
European Archives of Oto-Rhino-Laryngology
 
8.
Cigarette smoking causes epigenetic changes associated with cardiorenal fibrosis
Christopher A. Drummond, Laura E. Crotty Alexander, Steven T. Haller, Xiaoming Fan, Jeffrey X. Xie, David J. Kennedy, Jiang Liu, Yanling Yan, Dawn-Alita Hernandez, Denzil P. Mathew, Christopher J. Cooper, Joseph I. Shapiro, Jiang Tian
Physiological Genomics
 
9.
Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products
Michael John Peck, Edward B. Sanders, Gerhard Scherer, Frank Lüdicke, Rolf Weitkunat
Biomarkers
 
10.
Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
Harun Fajkovic, Shahrokh F. Shariat, Tobias Klatte, Mihai Dorin Vartolomei, Ilaria Lucca, Aurélie Mbeutcha, Morgan Rouprêt, Alberto Briganti, Pierre I. Karakiewicz, Vitaly Margulis, Michael Rink, Mesut Remzi, Christian Seitz, Karim Bensalah, Romain Mathieu
World Journal of Urology
 
11.
LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals
Wei Zhai, Yin Sun, Changcheng Guo, Guanghui Hu, Mingchao Wang, Jiayi Zheng, WanYing Lin, Qingbo Huang, Gonghui Li, Junhua Zheng, Chawnshang Chang
Cell Death and Differentiation
 
12.
Tobacco and end stage renal disease: a multicenter, cross-sectional study in Argentinian Northern Patagonia
Maria M. Alba, Alicia N. Citarelli, Fernanda Menni, Maria Agricola, Alejandra Braicovich, Eduardo De Horta, Fernando De Rosa, Graciela Filanino, Raul Gaggiotti, Nelson Junqueras, Sandra Martinelli, Adriana Milan, Mabel E. Morales, Silvia Setti, Daniel O. Villalba
Tobacco Induced Diseases
 
13.
Smoking has no impact on survival and it is not associated with ACE gene I/D polymorphism in hemodialysis patients
István Kiss, Zoltán Kiss, Lóránt Kerkovits, András Paksy, Csaba Ambrus
Journal of the Renin-Angiotensin-Aldosterone System
 
14.
Racial Disparities and Preventive Measures to Renal Cell Carcinoma
Jennifer Sims, Clement Yedjou, Daniel Abugri, Marinelle Payton, Timothy Turner, Lucio Miele, Paul Tchounwou
International Journal of Environmental Research and Public Health
 
15.
Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis
Debasish Kar, Clare Gillies, Mintu Nath, Kamlesh Khunti, Melanie J. Davies, Samuel Seidu
Acta Diabetologica
 
16.
Screening Assessment of Renal Function Status in Healthy Smoking Volunteers
Sayar R. Abdulkhakov, Evgenii V. Arkhipov, Rashat I. Faizullin, Irina V. Sidorova, Alina A. Ibragimova, Leila R. Gaysina, Julia V. Oslopova, Ekaterina Ju. Pronina, Dilyara D. Safina, Ildaria Kh. Valeeva, Vadim A. Salomatin, Evgeniya V. Gnuchikh, Evgeniya E. Arinina, Andrey P. Kiassov
BioNanoScience
 
eISSN:1617-9625